First Time Loading...

Amneal Pharmaceuticals Inc
NYSE:AMRX

Watchlist Manager
Amneal Pharmaceuticals Inc Logo
Amneal Pharmaceuticals Inc
NYSE:AMRX
Watchlist
Price: 6.69 USD -2.62%
Updated: May 16, 2024

Amneal Pharmaceuticals Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amneal Pharmaceuticals Inc
Cost of Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Amneal Pharmaceuticals Inc
NYSE:AMRX
Cost of Revenue
-$1.5B
CAGR 3-Years
-5%
CAGR 5-Years
-10%
CAGR 10-Years
-18%
Johnson & Johnson
NYSE:JNJ
Cost of Revenue
-$26.1B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Cost of Revenue
-$11B
CAGR 3-Years
-3%
CAGR 5-Years
-10%
CAGR 10-Years
-9%
Pfizer Inc
NYSE:PFE
Cost of Revenue
-$16.3B
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Merck & Co Inc
NYSE:MRK
Cost of Revenue
-$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Cost of Revenue
-$7.1B
CAGR 3-Years
-5%
CAGR 5-Years
-9%
CAGR 10-Years
-4%

See Also

What is Amneal Pharmaceuticals Inc's Cost of Revenue?
Cost of Revenue
-1.5B USD

Based on the financial report for Dec 31, 2023, Amneal Pharmaceuticals Inc's Cost of Revenue amounts to -1.5B USD.

What is Amneal Pharmaceuticals Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-18%

Over the last year, the Cost of Revenue growth was -9%. The average annual Cost of Revenue growth rates for Amneal Pharmaceuticals Inc have been -5% over the past three years , -10% over the past five years , and -18% over the past ten years .